Loading…
Insight Molecular Diagnostics Inc. is projected to rise to $5.10 by 2027, a +10% move from its current price of $4.65. IMDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $4.47 | $4.65 | $4.84 | +0.08% |
| Aug 5 | $4.40 | $4.66 | $4.93 | +0.15% |
| Aug 6 | $4.35 | $4.66 | $4.99 | +0.23% |
| Aug 7 | $4.31 | $4.66 | $5.05 | +0.30% |
| Aug 8 | $4.27 | $4.67 | $5.10 | +0.38% |
| Aug 9 | $4.24 | $4.67 | $5.15 | +0.46% |
| Aug 10 | $4.21 | $4.67 | $5.19 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.21 | $4.67 | $5.19 | +0.53% |
| Week 2 | $4.05 | $4.70 | $5.45 | +1.07% |
| Week 3 | $3.94 | $4.72 | $5.67 | +1.61% |
| Week 4 | $3.85 | $4.75 | $5.86 | +2.15% |
| Week 5 | $3.77 | $4.78 | $6.04 | +2.69% |
| Week 6 | $3.71 | $4.80 | $6.21 | +3.24% |
| Week 7 | $3.65 | $4.83 | $6.37 | +3.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc.
in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Insight Molecular Diagnostics Inc. (IMDX) is a healthcare company focused on precision diagnostics, offering a portfolio of laboratory developed tests, kitted tests, and related biomarker services. At its current price of $4.37 per share, the company has a market capitalization of $141.11M and ranks 4017 by market cap.
The stock trades below its short- and longer-term moving averages, with SMA50 at $5.45 and SMA200 at $5.48, and the 30-day range spanning from $3.34 to $5.72. The forecasted path shows a bullish long-term outlook, with rising average prices and ROIs across later years (for example, 2026 avg $4.37 and 2030 avg $9.14; 2050 avg $45.09).
A major floor 45.2% below — a decisive break under it would weaken the trend.
The nearest floor, 6.0% below — buyers have tended to step in here.
The nearest ceiling, 26.9% above — a clean break opens room to run.
A major ceiling 40.9% above — clearing it would confirm fresh momentum.
Key IMDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.59 | Buy | $4.62 | Buy |
| MA 10 | $4.75 | Sell | $4.70 | Sell |
| MA 20 | $4.80 | Sell | $4.85 | Sell |
| MA 50 | $5.40 | Sell | $5.06 | Sell |
| MA 100 | $4.81 | Sell | $5.10 | Sell |
| MA 200 | $5.48 | Sell | $4.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.45 | Neutral |
| Stoch RSI (14) | 64.80 | Neutral |
| CCI (20) | -54.48 | Neutral |
| Williams %R (14) | -55.56 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -3.53 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 44.44 | Neutral |
| TRIX (15) | -0.57 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 38.55 | Neutral |
| Momentum (10) | -0.09 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 4.45 | Buy |
| ADX (14) | 13.96 | Neutral |
| ATR (14) | 0.17 | Info |
The 30-day technical picture is Neutral. RSI14 is 40, placing price action in a middling zone. The stock trades below both the SMA50 ($5.45) and the SMA200 ($5.48). Near-term support is at $4.37 and resistance at $5.90. The 30-day range runs from $3.34 to $5.72, and annualized volatility sits at 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.55 | $4.65 | $6.55 | 0% | Neutral | |
| $3.90 | $5.10 | $7.14 | +10% | Neutral | |
| $4.56 | $6.23 | $9.19 | +34% | Bullish | |
| $5.41 | $7.66 | $11.76 | +65% | Bullish | |
| $6.96 | $10.18 | $16.14 | +119% | Bullish | |
| $7.84 | $11.81 | $19.27 | +154% | Bullish | |
| $6.99 | $10.83 | $18.13 | +133% | Bullish | |
| $7.68 | $12.22 | $20.91 | +163% | Bullish | |
| $8.55 | $13.95 | $24.37 | +200% | Bullish | |
| $9.23 | $15.43 | $27.49 | +232% | Bullish | |
| $11.85 | $22.20 | $42.83 | +378% | Bullish | |
| $24.45 | $54.34 | $117.42 | +10.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.55 | $4.65 | $5.61 | +0.00% |
| September 2026 | $3.87 | $4.64 | $5.76 | -0.24% |
| October 2026 | $4.12 | $4.98 | $6.28 | +7.43% |
| November 2026 | $4.25 | $5.18 | $6.61 | +3.98% |
| December 2026 | $4.13 | $5.08 | $6.55 | -1.96% |
Click any year to see its month-by-month IMDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMDX is projected to trade between $2.55 and $6.55, averaging $4.65 — a potential gain of 0% from today's $4.65. A consolidation phase looks the most probable path here.
Insight Molecular Diagnostics Inc.'s 2027 outlook centres on $5.10, within a $3.90 to $7.14 range. That is up +10% on the projected 2026 average. That marks a +10% change versus current levels. Price action looks broadly range-bound.
By 2028, IMDX could reach as high as $9.19, with a base case around $6.23 and support toward $4.56 — roughly +34% from $4.65. Buyers look set to stay in control over this stretch.
Expect IMDX to range from $5.41 to $11.76 through 2029. The $7.66 average target implies a +65% move from current prices. That is up +23% on the projected 2028 average. Momentum favours further upside here.
The IMDX price prediction for 2030 points to an average of $10.18 (low $6.96, high $16.14) — a potential gain of +119% on today's $4.65. Buyers look set to stay in control over this stretch.
In 2031, IMDX is projected to trade between $7.84 and $19.27, averaging $11.81 — a potential gain of +154% from today's $4.65. That is up +16% on the projected 2030 average. Momentum favours further upside here.
Insight Molecular Diagnostics Inc.'s 2032 outlook centres on $10.83, within a $6.99 to $18.13 range. That is -8% versus the projected 2031 average. That marks a +133% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, IMDX could reach as high as $20.91, with a base case around $12.22 and support toward $7.68 — roughly +163% from $4.65. Momentum favours further upside here.
Expect IMDX to range from $8.55 to $24.37 through 2034. The $13.95 average target implies a +200% move from current prices. That is up +14% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The IMDX price prediction for 2035 points to an average of $15.43 (low $9.23, high $27.49) — a potential gain of +232% on today's $4.65. Momentum favours further upside here.
In 2040, IMDX is projected to trade between $11.85 and $42.83, averaging $22.20 — a potential gain of +378% from today's $4.65. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Insight Molecular Diagnostics Inc.'s 2050 outlook centres on $54.34, within a $24.45 to $117.42 range. That is up +145% on the projected 2040 average. That marks a +10.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in IMDX today (≈ 215.053763 IMDX) could be worth
$11,685.57
+$10,685.57 (+1069%) by 2050 · US Dollar
Based on the average projected IMDX price of $54.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMDXwould be worth at today's price.
$1,000 invested in IMDX on Jul 31, 2025 (≈ 396.8254 IMDX) would be worth
$1,845.24
+$845.24 (+84.5%) today · 1.85× · US Dollar
Based on a IMDX entry price of $2.52 vs. today's $4.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.74 | $981.01 | -1.9% |
| 1 month ago | $5.69 | $817.22 | -18.3% |
| 3 months ago | $4.18 | $1,112.44 | +11.2% |
| 6 months ago | $6.86 | $677.84 | -32.2% |
| 1 year ago | $2.52 | $1,845.24 | +84.5% |
| All time (5.0y) ago | $93 | $50 | -95.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMDX forecast.
Our base-case forecast reaches $9.30 around 2030.
Implied market cap at $9.30: $300.3M
The multi-year forecast points to a bullish trajectory with rising averages and ROIs. In 2026 the avg price is $4.37 (min $2.55, max $6.14) with 0% ROI, turning bullish in later years as averages climb: 2027 avg $4.71 (ROI 7.7%), 2028 avg $5.64 (ROI 28.9%), 2029 avg $6.85 (ROI 56.8%), 2030 avg $9.14 (ROI 109.1%), 2031 avg $10.47 (ROI 139.6%), 2032 avg $9.50 (ROI 117.5%), 2033 avg $10.74 (ROI 145.7%), 2034 avg $12.03 (ROI 175.2%), 2035 avg $13.11 (ROI 200.1%), 2040 avg $18.58 (ROI 325.2%), and 2050 avg $45.09 (ROI 931.7%). The sentiment shifts from Neutral in 2026–2027 to Bullish from 2028 onward.
These figures are estimates and not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $9.14 with a max of $14.60 and a min of $6.20, and an ROI of 109.1%.
The long-term forecast is bullish from 2028 onward with rising averages and ROIs (e.g., 109.1% by 2030 and 931.7% by 2050), though 2026–2027 are Neutral and forecasts are estimates with inherent uncertainty.
No. The 2050 max in the forecast is $98.68, so $100 is beyond the modeled upper bound.
Current price is $4.37 and market cap is $141.11M.
The 30-day picture is Neutral with RSI14 at 40. SMA50 at $5.45 and SMA200 at $5.48. Support is $4.37, resistance $5.90, and the 30-day range is $3.34 to $5.72, with annualized volatility at 80%.
Insight Molecular Diagnostics Inc. Community Discussion
0Share your Insight Molecular Diagnostics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.